Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836703 | 0.85 | USP2 (1.00) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL12473499 | 0.83 | KMT2A (1.00) | USP2TSHRRAB9AALDH1A1MEN1 | |
| SCHEMBL15836698 | 0.83 | USP2 (1.00) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL6191409 | 0.83 | USP2 (0.70) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL15836704 | 0.81 | USP2 (0.81) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL12473143 | 0.75 | USP2 (0.74) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL15836705 | 0.75 | MEN1 (0.72) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL15836633 | 0.74 | TSHR (0.74) | USP2TSHRRAB9AALDH1A1GAA | |
| SCHEMBL108678 | 0.74 | KDM4E (0.70) | USP2TSHRMAPK1MEN1KMT2A | |
| SCHEMBL2056152 | 0.73 | KDM4E (0.62) | USP2TSHRALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | USP2 1628/4885TSHR 3057/4885RAB9A 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.